Publicaciones

• Filippi A, Alacqua M, Shakespeare A, Mazzaglia G, Bianchi C, Cowell W, Cricelli C. Management of atrial fibrillation with oral anticoagulants and predictors in clinical practice in Italy. Eur Heart J 2008;29(Abstract Supplement):534

• Perzborn E, Buetehorn U, Fischer E, Harwardt M, Klages M, Trabandt A. Hypercoagulability in rats is increased by low doses of the direct thrombin inhibitor melagatran , but is reduced by the direct factor Xa inhibitor rivaroxaban. Eur Heart J 2008;29(Abstract Supplement):825

• Klein M, Perzborn E, Laux V, Schäfer S, von Degenfeld G. The oral, direct factor Xa inhibitor rivaroxaban prevented right ventricular pressure increase and hypertrophy without increasing bleeding in a pulmonary artery hypertension model in rats. Eur Heart J 2008;29(Abstract Supplement):564

• Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kälebo P, Muelhofer E, Misselwitz F, Eriksson BI. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008;100:453-61.

• Kamphuisen PW. Thromboprophylaxis with rivaroxaban or enoxaparin did not differ for major bleeding or other safety outcomes in hip arthroplasty. ACP J Club. 2008 Nov-Dec;149(4):6-7.